Skip to main navigation Skip to search Skip to main content

High-sensitivity cardiac troponin i as a gatekeeper for coronary computed tomography angiography and stress testing in patients with acute chest pain

  • Maros Ferencik
  • , Thomas Mayrhofer
  • , Michael T. Lu
  • , Pamela K. Woodard
  • , Quynh A. Truong
  • , W. Frank Peacock
  • , Fabian Bamberg
  • , Benjamin C. Sun
  • , Jerome L. Fleg
  • , John T. Nagurney
  • , James E. Udelson
  • , Wolfgang Koenig
  • , James L. Januzzi
  • , Udo Hoffmann

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Most patients presenting to the emergency department (ED) with suspected acute coronary syndrome (ACS) undergo noninvasive cardiac testing with a low diagnostic yield. We determined whether a combination of high-sensitivity cardiac troponin I (hscTnI) and cardiovascular risk factors might improve selection of patients for cardiac testing. METHODS: We included patients from the Rule Out Myocardial Infarction/Ischemia Using Computer Assisted Tomography (ROMICAT) I and II trials who presented to the ED with acute chest pain and were referred for cardiac testing. Based on serial hs-cTnI measurements and cardiovascular risk factors, we derived and validated the criterion for no need of cardiac testing. We predicted the effect of this criterion on the effectiveness of patient management. RESULTS: A combination of baseline hs-cTnI (<4 ng/L) and cardiovascular risk factors (<2) ruled out ACS with a negative predictive value of 100% in ROMICAT I. We validated this criterion in ROMICAT II, identifying 29% patients as not needing cardiac testing. An additional 5% of patients were identified by adding no change or a decrease between baseline and 2 h hs-cTnI as a criterion. Assuming those patients would be discharged from the ED without cardiac testing, implementation of hs-cTnI would increase ED discharge rate (24.3% to 50.2%, P < 0.001) and decrease the length of hospital stay (21.4 to 8.2 h, P < 0.001), radiation dose (10.2 to 7.7 mSv, P < 0.001), and costs of care (4066 to 3342 US$, P < 0.001). CONCLUSIONS: We derived and validated a criterion for combined hs-cTnI and cardiovascular risk factors that identified acute chest pain patients with no need for cardiac testing and could improve effectiveness of patient management. ClinicalTrials.gov

Original languageEnglish (US)
Pages (from-to)1724-1733
Number of pages10
JournalClinical chemistry
Volume63
Issue number11
DOIs
StatePublished - Nov 2017

Funding

Roche; W. Koenig, AstraZeneca, Novartis, Pfizer, The Medicines Company, GSK, DalCor, Kowa, Amgen; J.L. Januzzi, Roche, Abbott, Philips. Stock Ownership: None declared. Honoraria: W.F. Peacock, Abbott, Beckman, Roche; F. Bamberg, Siemens Healthcare, Bayer Healthcare, Bracco; W. Koenig, AstraZeneca, Sanofi, Berlin-Chemie, Amgen; J.L. Januzzi, Roche. Research Funding: M. Ferencik, American Heart Association; P.K. Woodard, National Institutes of Health (U01HL092040). Siemens, Singulex; funding from Abbott and Roche to institution. Expert Testimony: None declared. Patents: None declared. Other Remuneration: W.F. Peacock, Abbott.

FundersFunder number
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of HealthU01HL092040
National Institute of Health National Heart, Lung, and Blood InstituteK24HL113128
American Heart Association/American Stroke Association

    ASJC Scopus subject areas

    • General Medicine

    Fingerprint

    Dive into the research topics of 'High-sensitivity cardiac troponin i as a gatekeeper for coronary computed tomography angiography and stress testing in patients with acute chest pain'. Together they form a unique fingerprint.

    Cite this